✦ LIBER ✦

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

✍ Scribed by Steven Boonen; Roman S. Lorenc; Dietrich Wenderoth; Karen J. Stoner; Rachelle Eusebio; Eric S. Orwoll

Book ID: 116325801
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 235 KB
Volume: 51
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2012.06.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-Weekly Risedronate in Men With Oste

Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study

✍ Steven Boonen; Eric S Orwoll; Dietrich Wenderoth; Karen J Stoner; Rachelle Euseb 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 479 KB

Efficacy and safety of alogliptin added

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

✍ K. Kaku; T. Itayasu; S. Hiroi; M. Hirayama; Y. Seino 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 564 KB

Efficacy and safety of alogliptin added

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

✍ Y. Seino; Y. Miyata; S. Hiroi; M. Hirayama; K. Kaku 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 632 KB

T.O.4 Safety and efficacy results from a

T.O.4 Safety and efficacy results from a randomized, double-blind, placebo-controlled study of alglucosidase alfa for the treatment of Pompe disease in juveniles and adults

✍ P. Laforet; P.R. Clemens; D. Corzo; D. Escolar; J. Florence; A. van der Ploeg; S 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4&#xa0;years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study